Compare IDYA & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | ATHM |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2019 | 2013 |
| Metric | IDYA | ATHM |
|---|---|---|
| Price | $35.41 | $22.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | ★ $49.33 | $28.00 |
| AVG Volume (30 Days) | ★ 964.1K | 442.2K |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 7.75% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | $214,834,000.00 | ★ $951,436,680.00 |
| Revenue This Year | $2,688.43 | N/A |
| Revenue Next Year | N/A | $2.29 |
| P/E Ratio | ★ N/A | $13.36 |
| Revenue Growth | ★ 5377.66 | N/A |
| 52 Week Low | $13.45 | $21.78 |
| 52 Week High | $39.28 | $32.70 |
| Indicator | IDYA | ATHM |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 47.76 |
| Support Level | $34.75 | $21.78 |
| Resistance Level | $37.81 | $23.48 |
| Average True Range (ATR) | 1.71 | 0.59 |
| MACD | -0.12 | 0.11 |
| Stochastic Oscillator | 42.11 | 65.00 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.